MARKET WIRESeekingAlpha • 3d ago
Nautilus Biotechnology: Bullish On Voyager's Upcoming LaunchExplore why Nautilus could be a long-term proteomics stock, with oncology expansion, research collaborations, and runway to launch Voyager.
Why NAUT Stock dropped -2.18% Today — RQD Quant Desk Flash
$3.14 -2.18% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $3.12
Nautilus Biotechnology Inc. (NAUT) carries a Roarable Rating of D- (Sell) with 41/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D- • RED ALERT
Cap $399.9M
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $3.12 (-0.58%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (41/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.2% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • D-
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D+
Each axis scored 0–20
12M PRICE TARGET CONE-7.6% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NAUT)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (41/100 Composite)
🔍 WHY NAUT SCORES 41/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Macro Regime Fit+12/20 pts (29% of score)
FRED Regime × Technicals: 66% of 52W Range • RSI-14 at 57.4 (BULLISH MOMENTUM)
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (24% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$2.25-8.4% Next Q
33
Q2 (-2Q)Grade E$2.06+57.3% Next Q
36
Q3 (-1Q)Grade E$3.24-3.1% Next Q
38
CurrentGrade D-$3.14-7.2% Hist 90D α
41
Trajectory: E (33) → D- (41)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a NAUT Turnaround Squeeze
While NAUT currently carries a cautious 41/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.59) and Max Pain ($3.30) forces dealer call-delta covering toward $4.53.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $NAUT• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “NAUT Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why NAUT Stock dropped -2.18% Today — RQD Quant Desk Flash
Nautilus Biotechnology Inc. (NAUT) dropped -2.18% to $3.14, trading at 66% of its 52-week range ($0.84 – $4.31). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 66% of its 52-week range ($0.84 – $4.31) with RSI-14 at 57.4 (BULLISH MOMENTUM).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $3.14 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D- (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live NAUT Headlines & Catalysts
MARKET WIREYahoo • 5d ago
Nautilus Biotechnology, Inc. Q3 2026 Earnings Call SummaryMoby summary of Nautilus Biotechnology, Inc.'s Q3 2026 earnings call
MARKET WIREYahoo • 5d ago
Nautilus (NAUT) Q3 2026 Earnings Call TranscriptCash reserves extend runway into early 2028 as proteoform assay pipeline accelerates.
MARKET WIREYahoo • 5d ago
Nautilus Biotechnology Q3 Earnings Call HighlightsNautilus Biotechnology (NASDAQ:NAUT) reported third-quarter revenue of $200,000 as it continued its transition toward commercialization of its Voyager proteomics platform, with management reaffirming plans to begin takin
MARKET WIRESeekingAlpha • 5d ago
Nautilus Biotechnology, Inc. (NAUT) Q3 2026 Earnings Call TranscriptNautilus Biotechnology, Inc. (NAUT) Q3 2026 Earnings Call October 27, 2026 8:30 AM EDTCompany ParticipantsSujal Patel - Co-Founder, CEO, President,...
CATALYSTChartMill • 5d ago
Nautilus Biotechnology (NASDAQ:NAUT) Q3 Earnings Beat and Pipeline Progress Drive Premarket SurgeNautilus Biotech (NASDAQ:NAUT) Q3 2026 revenue and EPS beat consensus, stock up 45% premarket on upside surprise and steady proteomics pipeline progress.
MARKET WIREYahoo • 5d ago
Nautilus to Measure Proteoforms Driving Alzheimer’s Disease and Cancer in ARPA-H-Funded SEEDS ConsortiumNautilus expects to receive up to $6 million to bring its Voyager™ Platform to a multidisciplinary team integrating protein science, AI, and computational modeling to develop new diagnostics and therapeuticsSEATTLE, Oct.
MARKET WIREYahoo • 5d ago
Nautilus Biotechnology Reports Third Quarter 2026 Financial ResultsSEATTLE, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the third quarter ended Sept
MARKET WIREBenzinga • 5d ago
Nautilus Biotechnology Q3 2026 Earnings Call TranscriptNautilus Biotechnology (NASDAQ:NAUT) reported third-quarter financial results on Tuesday. The transcript from the company’s third-quarter earnings call has been provided below.Benzinga APIs provide real-time access to
CATALYSTBenzinga • 5d ago
Nautilus Biotechnology Announces Participation In SEEDS Research Consortium, Which Was Awarded Up To $51.7M By The Advanced Research Projects Agency For HealthNautilus Biotechnology, Inc. (NASDAQ:NAUT), a company pioneering intact, single-molecule proteomics approaches, today announced its participation in SEEDS (Sequence-to-disease: Environment-aware Ensembles of Disordered
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring NAUT)
- ✓Walkthrough of NAUT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
NAUT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +19.39%▲ RESISTANCE BREAKOUT
2026-10-30O $2.88H $3.14L $2.64C $3.14VOL 8.05M
RES: $2.60SUP: $0.93SMA50: $1.59SMA200: $2.12
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
NAUT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on NAUT today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for NAUT. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for NAUT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NAUT)
Health Care Rank #608 of 1016
⚔️ LAB vs NAUT Full Matrix →
1. Head-to-Head Health Care Peer Comparison (NAUT vs. LAB, CTKB, PACB, QTRX)
Industry: Biotechnology: Laboratory Analytical Instruments (21 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Nautilus Biotechnology Inc. (NAUT) ranks #608 by composite RQD confidence (41/100, grade D-) and #480 by equity capitalization ($399.9M). Within this direct 5-issuer industry benchmark cohort, NAUT leads on earnings valuation at N/A trailing P/E, while CTKB leads on capital efficiency and profitability with -12.7% ROIC and 51.8% gross margin. NAUT currently leads its immediate peer cohort in composite quantitative strength at 41/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| NAUT
ACTIVE
Nautilus Biotechnology Inc. | D- | 41/100 | — | — | -35.0% | -2.18% | $399.9M | Benchmark Subject |
| LAB Standard BioTools Inc. | D- | 41/100 | — | 49.9% | -28.7% | +0.49% | $244.7M | /lab-vs-naut → |
| CTKB Cytek Biosciences Inc. | D- | 41/100 | — | 51.8% | -12.7% | +2.61% | $818.9M | /ctkb-vs-naut → |
| PACB Pacific Biosciences of California Inc. | D- | 37/100 | — | 28.6% | -35.0% | +2.47% | $901.4M | /pacb-vs-naut → |
| QTRX Quanterix Corporation | E | 28/100 | — | 46.8% | -35.0% | +0.80% | $148.7M | /qtrx-vs-naut → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001808805In its most recent audited fiscal period (FY2025, filed 2025-12-31), Nautilus Biotechnology Inc. (NAUT) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$59.0M, operating cash flow of -$50.7M, and free cash flow of -$52.0M (+15.2% YoY). On the balance sheet, NAUT closed FY2025 with $191.1M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$59.0M | -$50.7M | -$52.0M | $191.1M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$70.8M | -$59.1M | -$61.3M | $242.7M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$63.7M | -$51.7M | -$51.7M | — | — |
3. NAUT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs NAUT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Nautilus Biotechnology Inc. (NASDAQ: NAUT) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 41/100 at a spot price of $3.14 (-2.18% 1D, market cap $399.9M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, NAUT ranks #608 in composite RQD confidence.
How does NAUT compare to LAB and CTKB in the Health Care sector?
Within the Health Care sector (Biotechnology: Laboratory Analytical Instruments), NAUT carries a Roarable D- (41/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, LAB (Standard BioTools Inc.) holds a D- grade (41/100 RQD, P/E N/A, ROIC -28.7%, cap $244.7M) and CTKB (Cytek Biosciences Inc.) posts a D- grade (41/100 RQD, P/E N/A, ROIC -12.7%, cap $818.9M). Among the 5-stock peer group, NAUT leads on earnings multiple (N/A) while CTKB leads on capital efficiency (-12.7% ROIC).
What are the biggest fundamental strengths and SEC risk factors for NAUT?
Per NAUT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001808805), Nautilus Biotechnology Inc. generated $0 in revenue, -$59.0M in net income, and -$52.0M in free cash flow against $191.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is NAUT trading relative to its 50-day, 200-day, and 52-week technical levels?
NAUT last traded at $3.14 (-2.18% on volume of 7,509,013 shares), positioning the stock +97.48% above its 50-day simple moving average ($1.59) and +48.11% above its 200-day simple moving average ($2.12). Across its 52-week range of $0.84 to $4.31, NAUT sits at the 66.3% percentile with a 14-day RSI of 57.4 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($2.75 to $3.53).
NAUT Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is NAUT stock moving today?
Why NAUT Stock dropped -2.18% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.